<DOC>
	<DOCNO>NCT01548495</DOCNO>
	<brief_summary>The purpose study verify present autoantibody serums MDS serum patient inadequate response respond Recombinant human erythropoietin ( rHuEPO ) treatment .</brief_summary>
	<brief_title>Autoantibodies Against Human Recombinant Erythropoietin Myelodysplatic Syndrome Patients</brief_title>
	<detailed_description>MDS heterogeneous group hematologic disorder broadly characterize cytopenia associate dimorphic usually cellular bone marrow , consequent ineffective blood cell production . 85 % patient severe anemia Associated lower quality life Often require blood transfusion . Historically , stem cell transplantation offer cure . however , multiple new drug approve treatment , Recombinant human erythropoietin ( rHuEPO ) treatment deal anemia . rHuEPO treatment improve hematocrit level 25 % patient leave rest need treatment solution . Studies show present anti- rHuEPO blood serum follow Treatment disease . These finding indicate possibility presence antibody MDS patient well .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<criteria>Followed hematological patient Pateint recieving rHuEPO treatment ( except control group ) Pateint sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>MDS</keyword>
	<keyword>Autoantibodies</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Autoantibodies MDS patient treat EPO</keyword>
</DOC>